Results 21 to 30 of about 260,030 (390)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS [PDF]

Nature Communications, 2020
AbstractTumour-associated KRAS mutations are the most prevalent in the three RAS-family isoforms and involve many different amino-acids. Therefore, molecules able to interfere with mutant KRAS protein are potentially important for wide-ranging tumour therapy.
Nicolas Bery, Nicolas Bery, Terry Rabbitts, Ami Miller   +3 more
openaire   +6 more sources

Combined analysis of KRAS mutation and p16INK4a and p14ARF methylation status in locally advanced rectal carcinoma treated with preoperative chemoradiotherapy [PDF]

Archives of Biological Sciences, 2022
Current management of locally advanced rectal carcinoma (LARC) involves preoperative chemoradiotherapy (preCRT) before surgery. Despite improved local control rate, the response to preCRT of individual patients is variable and may reflect heterogeneous ...
Kožik Bojana R., Krajnović Milena M., Kokanov Nikola S., Jovanović-Ćupić Snežana P., Božović Ana M., Todorović Lidija B., Mandušić Vesna Lj.   +6 more
doaj   +1 more source

Oncogenic KRAS drives lipo-fibrogenesis to promote angiogenesis and colon cancer progression.

Cancer Discovery, 2023
Oncogenic KRAS (KRAS*) contributes to many cancer hallmarks. In colorectal cancer (CRC), KRAS* suppresses anti-tumor immunity to promote tumor invasion and metastasis.
Wen-Hao Hsu, Kyle Labella, Yiyu Lin, Ping Xu, Rumi Lee, Cheng-En Hsieh, Lei Yang, Ashley Zhou, Jonathan M Blecher, Chang-Jiun Wu, Kangyu Lin, Xiaoying Shang, Shan Jiang, D. Spring, Yan Xia, Peiwen Chen, J. P. Shen, S. Kopetz, Ronald A. DePinho   +18 more
semanticscholar   +1 more source

Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer

Archives of Medical Science, 2021
Introduction Detection of abnormalities in the KRAS, NRAS and BRAF genes is extremely important for proper qualification of colorectal cancer (CRC) patients for therapy with anti-EGFR (epidermal growth factor receptor) monoclonal antibodies.
Aleksandra Bożyk, Paweł Krawczyk, Katarzyna Reszka, Kinga Krukowska, Agnieszka Kolak, Sławomir Mańdziuk, Kamila Wojas-Krawczyk, Rodryg Ramlau, Janusz Milanowski   +8 more
doaj   +1 more source

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer

Molecular Cancer, 2021
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive ...
Gongmin Zhu, Lijiao Pei, Hongwei Xia, Qiu-lin Tang, F. Bi   +4 more
semanticscholar   +1 more source

Menulis Teks Eksplanasi Ilmiah Dengan Menggunakan Media Media Flash Card

Ibriez: Jurnal Kependidikan Dasar Islam Berbasis Sains, 2019
Kemampuan menulis kelas VI sekolah dasar adalah kemampuan menulis teks penjelasan (eksplanasi) dengan menggunakan kosa kata baku dan kalimat efektif. Namun pada kenyataannya, siswa kelas VI SDN Rejomulyo 1 Kras Kediri masih kesulitan menulis karangan ...
Bambang Setyawan
doaj   +1 more source

Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer

Cancers, 2023
Simple Summary KRAS plays an important role in transmitting signals from growth factors on the outside of the cell to the cell nucleus. It regulates cell proliferation, growth, and survival.
Éabha O’Sullivan, A. Keogh, Brian Henderson, S. Finn, S. Gray, K. Gately   +5 more
semanticscholar   +1 more source

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies [PDF]

Frontiers in Oncology, 2022
Approximately 20% of lung adenocarcinomas harbor KRAS mutations, an oncogene that drives tumorigenesis and has the ability to alter the immune system and the tumor immune microenvironment. While KRAS was considered “undruggable” for decades, specific KRAS G12C covalent inhibitors have recently emerged, although their promising results are limited to a ...
Marc Cucurull, Marc Cucurull, Lucia Notario, Lucia Notario, Montse Sanchez-Cespedes, Cinta Hierro, Cinta Hierro, Anna Estival, Anna Estival, Enric Carcereny, Enric Carcereny, Maria Saigí, Maria Saigí   +12 more
openaire   +4 more sources

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer [PDF]

, 2017
KRAS mutated tumours represent a large fraction of human cancers, but the vast majority remains refractory to current clinical therapies. Thus, a deeper understanding of the molecular mechanisms triggered by KRAS oncogene may yield alternative ...
Andersen, Jesper B., Arricibita, Andrea, Bailey, Peter, Biankin, Andrew, Bozec, Aline, Chang, David K., Chuang, Chen-Hua, Guembe, Laura, Guruceaga, Elisabet, Gwinn, Dana, Khatri, Purvesh, Lecanda, Fernando, Martinez-Canarias, Susana, Mazur, Pawel K., Perurena, Naiara, Ponz-Sarvise, Mariano, Sage, Julien, Sayles, Leanne C., Sweet-Cordero, E. Alejandro, Valencia, Karmele, Vallejo, Adrian, Vicent, Silve, Zandueta, Carolina   +22 more
core   +3 more sources

Genetic background influences tumour development in heterozygous Men1 knockout mice [PDF]

, 2020
Multiple endocrine neoplasia type 1 (MEN1), an autosomal dominant disorder caused by MEN1 germline mutations, is characterised by parathyroid, pancreatic and pituitary tumours. MEN1 mutations also cause familial isolated primary hyperparathyroidism (FIHP)
Christie, Paul T., Javid, Mahsa, Kooblall, Kreepa G., Lines, Kate E., Mallon, Ann-Marie, Newey, Paul J., Piret, Sian E., Reed, Anita Ac, Simon, Michelle, Stevenson, Mark, Thakker, Rajesh V., Walls, Gerard V.   +11 more
core   +2 more sources